Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Fernandes, AR (Author) Other; Zielinska, A (Author) Other; Sanchez Lopez, E (Author) Other; dos Santos, T (Author) Other; Garcia, ML (Author) Other; Silva, AM (Author) Other; Karczewski, J (Author) Other; Souto, EB (Author) FFUP

Journal

Title: International Journal Of Molecular Sciences

Vol. 23

Final page: 2592

ISSN: 1661-6596

Publisher: MDPI

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 2 Citations

Other information

Authenticus ID: P-00W-7XX

DOI: 10.3390/ijms23052592

Abstract (EN): Age-related macular degeneration (AMD) is an eye disease typically associated with the aging and can be classified into two types-namely, the exudative and the nonexudative AMD. Currently available treatments for exudative AMD use intravitreal injections, which are associated with high risk of infection that can lead to endophthalmitis, while no successful treatments yet exist for the nonexudative form of AMD. In addition to the pharmacologic therapies administered by intravitreal injection already approved by the Food and Drug Administration (FDA) in exudative AMD, there are some laser treatments approved that can be used in combination with the pharmacological therapies. In this review, we discuss the latest developments of treatment options for AMD. Relevant literature available from 1993 was used, which included original articles and reviews available in PubMed database and also information collected from Clinical Trials Gov website using age-related macular degeneration and antiangiogenic therapies as keywords. The clinical trials search was limited to ongoing trials from 2015 to date.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 23